Several retrospective data analyses of patients with diabetes taking antipsychotics have yielded an increased risk of either development or exacerbation of this metabolic condition-up to 3 times the risk with olanzapine, 7 times the risk with clozapine, and 2 times the risk with conventional high-potency antipsychotics (1) .
Therefore, careful and regular monitoring for diabetes pre-and posttreatment continues to remain a significant part of the psychopharmacotherapy of schizophrenia. The availability of newer antipsychotics such as ziprasidone and aripiprazole may be a step forward in managing this situation. combined with an age-related further loss of cholinergic integrity also plays a prominent role (1) . Treating this complication is difficult: because of their selective dopamine receptor antagonistic effects, most typical antipsychotic drugs worsen motor symptoms of Parkinson's disease. As a consequence of a nonselective antagonism at both serotonergic and dopaminergic receptors, atypical antipsychotics such as clozapine or olanzapine are associated with fewer extrapyramidal side effects (2) . Clozapine was the first atypical antipsychotic drug to be introduced into clinical use in several European countries, in the late 1960s (3). Clozapine treatment is associated with wide side effects that include the following: blood-cell dyscrasias, benign granulocytopenia, transient granulocytosis, and a risk of agranulocytosis as high as 0.5% to 1% (4); transient fever in up to 50% of the patients; sedation; and considerable body-weight gain. The mechanisms underlying these side effects are still unknown, but recent data suggest that the metabolism of clozapine and its immunomodulatory effects may play a role. Aplastic anemia in all its features emerging during clozapine therapy has not been documented in the literature. We present a case of clozapine-induced aplastic anemia.
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Case Report
A 53-year-old man with Parkinson's disease (according to ICD-10 criteria) developed a dopamine-induced psychosis with hallucinations. Because of his persisting psychotic symptoms, he was admitted to a psychiatric hospital, and antipsychotic pharmacotherapy of 50 mg clozapine daily was started. He developed fever after 1 week, and his blood tests revealed abnormalities (neutrophil count < 500/L, platelet count 93 000/L, and reticulocyte count < 20 000/L). Clozapine therapy was discontinued and he was admitted to our clinic. According to the criteria of the International Aplastic Anemia Study Group, we diagnosed a severe form of drug-induced aplastic anemia (neutrophil count < 500/L, platelet count 89 000/L, and reticulocyte count < 20 000/L). He received blood transfusions, and we started therapy with hematopoietic growth factors (r-metHuG-CSF) (5) and
antibiotics. The Parkinson's disease was treated with dopamine and apomorphine. After 14 days, he was responding to the therapy, and the aplastic anemia disappeared. The psychosis with delusions and hallucinations was still evident, and we established a neuroleptic therapy with quetiapine. The therapy with hematopoietic growth factors was discontinued.
We hypothesize that clozapine induced the severe aplastic anemia. The major classes of myelotoxic drugs are known, but the mechanisms by which certain agents cause aplastic anemia are still unclear. We suggest cautious use of clozapine in patients with Parkison's disease.
Marc Ziegenbein, MD; Anja Steinbrecher, MD; Petra Garlipp, MD Hannover, Germany
Early-Onset Obsessive-Compulsive Disorder
Dear Editor:
Studies have reported high prevalence rates (6-month prevalence of 0.5% to 1%) of obsessive-compulsive disorder (OCD) in children and adolescents (1) . Although the childhood onset-age of OCD in most clinical samples has ranged from age 6 to 11 years (2), the disorder has been found in children as young as age 3 years. We report the case of patient with early-onset OCD who presented for psychiatric consultation many years after the onset of illness.
Case Report
Mr A, age 16 years, is a slow-to-warm-up high-school student from a middle socioeconomic background. He presented for the first time to the clinic with a 2½-year history of school refusal and irritability. On clarification, it was apparent that from a very young age (even before age 5 years) he was excessively concerned about dirt. He would avoid looking at the toilet, even while using it, take an abnormally long time washing his face (his clothes getting wet in the process) and bathing, and would not allow anyone to use his towels. He would also avoid using toilets outside his own house whenever he went on a trip. About 2½ years before presenting to the clinic, he also began to have obsessive images of a dirty bathroom and toilet. Further, he began to fear that he would forget lessons studied and, hence, fail to answer either in class or during examinations. Consequently, he avoided exams and refused to go to school. He also thought that people were talking about him on the road and had checking compulsions yielding to these obsessive doubts, fears that books given to friends might get lost, compulsive reassurance seeking, repeated intrusive ruminations about events during the day, and thoughts that he would be responsible for something bad happening. He was also found to have a history suggesting separation anxiety disorder of childhood, sibling rivalry, and oppositional tendencies, for which psychiatric consultation had not been sought. The family history suggested unspecified mental illness in his maternal grand-aunt and maternal uncle, possible depressive illness in his paternal great-grandmother, and subclinical obsessive-compulsive symptoms in his mother's maternal uncle. Although he had poor insight and was uncooperative for treatment at the time of presentation, he started showing response to sertraline (up to 150 mg daily). Later, he started cooperating with exposure-and response-prevention therapy for his contamination obsessions and with audioexposure therapy for his obsessive fear of forgetting lessons learned. At the end of 4 weeks' inpatient treatment, his obsessions and compulsions showed significant improvement.
This case highlights the fact that OCD may have onset at a very early age and is in keeping with the earlier findings of early onset being associated with male sex and positive family history (3). The long time-lag before this case actually presented to a psychiatrist indicates the need for increased awareness among professionals, especially because the illness arises at a developmentally important period.
Dr Sagnik Bhattacharyya, DPM, DNB, MD; Dr Girishchandra BG, DPM, DNB; Dr Sumant Khanna, MD, MNAMS, MRCPsych, PhD Bangalore, India
Treatment Noncompliance With Orally Disintegrating Olanzapine Tablets
Recently, Chue and colleagues suggested that new formulations of antipsychotics that are fast-dissolving in the mouth, such as orally disintegrating olanzapine tablets, are welcome. They are seemingly impossible to "cheek" and may improve medication adherence (1) . In selected patients, this is true. However, such novel drug formulations are no panacea against noncompliance, which was exemplified by a patient who managed to be noncompliant with fast-dissolving olanzapine tablets (2).
Case Report
Ms A was a 52-year-old woman with chronic schizophrenia and tardive dyskinesia and a long history of noncompliance with antipsychotics, resulting in a cyclical pattern of hospitalizations that alternated with homelessness. Untreated, she was hostile, disorganized, and dishevelled. With antipsychotic treatment, she was pleasant, was able to follow ward routines, and took pride in her appearance, with great concern for potential weight gain. She never regarded herself as ill and always denied the need for medication.
After being involuntarily hospitalized, a 6-month clozapine trial failed, because the patient remained adversarial to taking medications. Despite great staff effort, she decompensated twice in hospital, owing to noncompliance (corroborated by plasma levels).
After she agreed to try out this newly formulated medicine, an olanzapine wafer trial was initiated. Although she was apparently compliant, no clinical improvement occurred after several weeks of olanzapine wafers at a dosage of 20 mg daily. A steady-state olanzapine plasma level was unexpectedly low (8.5 ng/mL). Finally, a nurse observed the following "cheeking" technique: the patient put the Zydis wafer up behind her front teeth near the gum line. It appeared that she kept her mouth dry to allow the wafer to stick in place. In this way, she managed to produce the wafer largely intact, minutes after it was administered. After this experience, she was started on haloperidol decanoate.
